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Available online 1 July 2016In Gaucher disease (GD) imaging of liver and spleen is part of routine follow-up of GD patients. Focal lesions in
both liver and spleen are frequently reported at radiological examinations. These lesions often represent benign
accumulations of Gaucher cells, so-called “gaucheroma”, but malignancies, especially hepatocellular carcinoma,
are more frequently found in GD as well. We report the imaging characteristics of all focal lesions in liver and
spleen in the Dutch GD cohort. Of the 95 GD1 patients, 40% had focal splenic and/or hepatic lesions, associated
with more severe GD. Lesions identiﬁed as gaucheroma have variable imaging characteristics: hyper- to
hypointense onMRI, hyper- or hypoechoic onUS and hypodense on computed tomography (CT). Hepatic lesions
were classiﬁed as simple cysts or haemangioma based upon imaging characteristics. Focal nodular hyperplasia
(FNH), gaucheroma and hepatocellular carcinoma (HCC) could not be distinguished by conventional US, CT or
MRI. Growth of these lesions and/or characteristics ofHCC ondynamic CT orMRI and pathologywas used to iden-
tify or rule out HCC. We propose a decision-making algorithm including the use of growth and dynamic CT- or
MRI-scanning to characterize lesions.ular carc
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Follow-up1. Introduction
Gaucher disease (GD; Online Mendelian Inheritance in Man
#230800) is a rare lysosomal storage disorder in which the lysosomal
enzyme glucocerebrosidase (GBA1) is deﬁcient. This deﬁciency leads
to accumulation of the glycosphingolipid glucosylceramide, a compo-
nent of cell membranes [1]. Accumulation takes place in macrophages,
which can be engorged with glucosylceramide. The lipid-laden macro-
phages, Gaucher cells, are mainly found in spleen, liver and bone mar-
row. Clinical manifestations include hepatosplenomegaly, anemia,
thrombocytopenia, leukopenia, bone pain, avascular bone necrosis,
pathologic fractures and vertebral compression. The occurrence of
symptoms is subject to variety in each affected individual and the
onset of symptomatology can occur at any age. GD is classically catego-
rized into three phenotypic variants, of which type 1 (GD1) is the mostinoma; MRI, magnetic
d; FNH, focal nodular
herapy; SRT, substrate
e/Endocrinology and
AZ Amsterdam, The
n open access article undercommon [2,3]. Over the years it has become clear that GD is associated
with an increased risk of developingmalignancies. Amongst others, he-
patocellular carcinoma (HCC), multiplemyeloma and other hematolog-
ical malignancies have been described [4–6].
Since more than two decades, enzyme replacement therapy (ERT) is
available for treatment of GD. ERT is able to reduce liver- and spleen
volumes and to improve cytopenia and bone disease [7,8]. Centers of
expertise have implemented protocols for follow-up of their patients
to assess bone marrow involvement and regular monitoring of
hepatosplenomegaly usingmagnetic resonance imaging (MRI) or ultra-
sonography (US) is widely applied [9–12]. During these routine assess-
ments, a frequently encountered phenomenon is the appearance of
focal splenic and/or hepatic lesions [13]. Some of these lesions are
thought to be benign clusters of Gaucher cells, so-called ‘gaucheroma’.
However, gaucheroma can show major variance in their imaging char-
acteristics and can be incorrectly considered to be a neoplasm such as
lymphoma or HCC [14]. The frequent occurrence of focal lesions in
spleen and liver in GD patients leads to a challenge in determining the
most appropriate follow-up for each individual.
With this study we aim to provide an overview of the imaging char-
acteristics of different focal splenic and hepatic lesions found in adult
GD1 patients in our population. A secondary aim of this paper is to com-
pare disease characteristics of patientswith andwithout focal hepatic orthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Examples of CT ﬁndings of splenic lesions, suggestive of gaucheroma. A. CT-examination of a 54-years oldmale patient showingmultiple hypodense lesions in the spleen. Note the
calciﬁcations (arrow) B. Two hypodensities of the spleen in a 35-years old female.
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follow-up recommendations to aid in the clinical decision-making in
GD1 patients with focal splenic and/or hepatic lesions.
2. Methods
The Academic Medical Center in Amsterdam is the center of excel-
lence for GD patients in The Netherlands.We performed a retrospective
review of all available imaging reports of 95 adult GD1 patients evaluat-
ed at our clinic from 1990 until 2015. All patients were diagnosed with
GD based on low glucocerebrosidase activity in peripheral blood
leucocytes and genotyping of the GBA1-gene.Fig. 2.MRI ﬁndings in four GD patients with focal splenic lesions. A. Enlarged spleenwith a hete
intensity. B. A 58-years old female patient with a round, mainly hyperintense lesion on T1w im
patient aged 74 years.2.1. Imaging protocols
During follow-up of GD1 patients at our center, liver and spleen vol-
umes are measured at regular intervals both in treated and untreated
patients. In the nineties, non-contrast enhanced single slice CT-scanning
was used for this purpose, replaced by non-contrast enhanced T1-
weighted MRI later on. This latter approach limits radiation exposure
and can be obtained directly after the regular bonemarrowMRI assess-
ments. The restriction of this MRI-protocol with T1-weighted series
only is the limited ability to assess the parenchyma in detail and,
when present, characterize focal lesions. In case of incidental hepatic
or splenic lesions, ultrasound (US) examination is usually initiallyrogeneous aspect in a 47-years old GD1male patient, several focal lesions of mixed signal
age of the spleen. C. Small hyperintense splenic nodule (see arrow) in the spleen of a male
Fig. 3. Examples of US ﬁndings in GD patients. A. hyperechoic lesion in the spleen of a 29-years old female. Differential diagnosis: haemangioma or gaucheroma (case no.32) B. Two
hypodense splenic lesions in a male patient 52 years of age, most likely gaucheroma.
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logic examinationsmay follow. Because of the increased risk to develop
HCC, we have implemented a protocol to examine all splenectomized
GD1 patients with US of the liver every six months.
2.2. Data acquisition and analysis
The following parameters were recorded for each patient: gender,
genotype, spleen status, pre-treatment severity score index (SSI) [15],
pre-treatment chitotriosidase level, pre-treatment liver- and spleen vol-
ume, presence of bone complications, site of focal lesions (liver, spleen
or both) and imaging modalities performed (US, CT or MRI, either
with or without contrast enhancement). Characteristics of GD1 patients
at baseline, i.e. before treatment or for untreated patients, the ﬁrst date
of imaging at our center, were compared for groups with and without
focal lesions in spleen and/or liver. For statistical calculations SPSS ver-
sion 22.0 was used (SPSS Inc. Chicago, Illinois, USA). Baseline character-
istics of patients are reported inmedians and ranges, and in percentages
for categorical data. To compare differences between these cohorts,
Mann-Whitney U test for continuous data or chi-squared test for cate-
gorical outcomes was performed. A p-value of b0.05 was considered
statistically signiﬁcant.
Reported focal lesions in spleen and/or liver were reviewed by an ex-
pert panel consistingof two radiologists (O.v.D., I.S.)with expertise in the
abdominal imaging ﬁeld. This expert panel was blinded to radiology andFig. 4.Hepatic lesions foundonMRI-scanning (T1-weighted images), indicated by red arrows. A
male of 62 years. B. Hypointense lesion, differential diagnosis: hemangioma or Gaucheroma, inpathology reports. Imaging characteristics of the lesions were recorded
per available imaging modality and agreement on the differential diag-
nosis was obtained. General features of the lesions found are summa-
rized and a comparison of our ﬁndings to existing literature is made.3. Results
Thirty-eight of the 95 GD1 patients (40%) had a focal lesion in liver
and/or spleen reported at least once during follow-up. Twenty-three pa-
tients (24%) showed focal splenic lesions and in twenty-four patients
(25%) hepatic lesions were reported. In nine patients focal lesions
were found both in spleen and liver. Table 1 summarizes the baseline
patient characteristics of all patients. Patients in the groupwith focal le-
sions did not differ from the group without lesions regarding sex, num-
ber of splenectomies, age and genotypes. Compared to the 38 patients
with focal lesions, the 57 patients without lesions showed a somewhat
less severe GD, based on a lower median SSI-score (p = 0.01), lower
median chitotriosidase levels (p = 0.035), lower median spleen vol-
umes (p= 0.009) and a lower proportion of patients with a history of
bone complications (p=0.003). If we exclude patients with splenic le-
sions from the analysis, the group with focal liver lesions comprises a
statistically signiﬁcant higher percentage of splenectomized patients
as compared to patients without lesions in the liver (50% versus 24%,
p= 0.017).. Hyperintense lesion cranial in liver, differential diagnosis: FNH or Gaucheroma. Patient is a
a female patient aged 28 years.
Fig. 5. Examples of focal lesions on US in livers of GD patients, indicated by white crosses. A. hypoechoic lesion, corresponding to the MRI in Fig. 4A, in a 62 years old patient. Differential
diagnosis: FNHof gaucheroma. B. Hyperechoic lesion in the liver of a 32 years old female, based on additionalMRI examination, this lesion is thought to be a hemangioma. C. Typical aspect
of a simple cyst in a 58 years old female.
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In twenty-three patients focal lesions of the spleen were described.
Twenty patients had multiple splenic lesions. CT-examinations were
available in 15, in which splenic lesions all appeared hypodense
(see Fig. 1). Contrast-enhanced CT-images were available in three pa-
tients, with one lesion showing slight enhancement of the rim (no. 7).
On (non-contrast enhanced) T1-weighted MR-images focal lesions ap-
peared hyperintense in ﬁve patients, hypointense in three patients
and mixed hypo-/hyperintense signal in four patients. One patient
(no. 35) showed hyperintense and mixed signal intensity lesions on
T1-weighted images. MRI with contrast performed in one patient
(no. 4) showing no contrast enhancement of the focal splenic lesion.
T2-weighted MR-images were available in four patients; two patients
had hyperintense lesions and in two patients the lesions appeared
hypointense. Examples of splenic lesions found on MRI-examination
are given in Fig. 2. US-examinations were reviewed in 15 patients, ex-
amples are depicted in Fig. 3. Focal splenic lesions appearedhyperechoic
in six patients, hypoechoic in four patients and mixed signal lesions
were noted in three cases. Two patients hadmultiple lesions of different
echogenicity within the spleen. In ﬁve patients calciﬁcations in splenic
lesions were present. For the majority of lesions, a follow-up of several
years was available and no malignant transformation of any of the
splenic lesions was observed, nor did splenic lymphoma occur.
In addition, while the presence of lymphadenopathy was not
within the scope of the present study, in none of the patients
with splenic or hepatic lesions the presence of lymphadenopathy was
reported. No pathologic examinations of splenic lesions were available.
In all cases, the most likely diagnosis was gaucheroma. Two
splenectomized patients had small, calciﬁed accessory spleens ofTable 1
Baseline characteristics of all patients (with and without focal lesions). SSI = severity
score index, NA not applicable, NS not signiﬁcant.
Focal lesions
liver/spleen
No focal lesions
liver/spleen
p-value
No. of patients (%) 38 (40%) 57 (60%) NA
Men, no. (%) 20 (53%) 30 (53%) NS
Age in 2016 (years), median
(range)
56.0 (27–92) 50.5 (21–82) NS
Splenectomies, no. (%) 12 (32%) 17 (30%) NS
SSI-score, median (range) 7 (2–19) 6 (1–19) 0.01
Chitotriosidase (nmol/ml/h),
median (range)
31,133
(3701–98,992)
23,080
(2964–143,458)
0.035
Presence of bone
complications, no. (%)
25 (66%) 20 (35%) 0.003
Genotype N370S/L444P, no. (%) 12 (32%) 22 (39%) NS
Liver volume (ml), median
(range)
2831
(1076–6542)
2228 (1213–5814) NS
Spleen volume (ml), median
(range)
1688
(145–5358)
885 (113–3354) 0.00910 mm and 13 mm respectively, without signs of gaucheroma. Over
time, these accessory spleens did not change with respect to character-
istics or size. Table 2 summarizes the imaging characteristics of all
splenic lesions.3.2. Hepatic lesions
Focal hepatic lesions were found in twenty-four patients, of whom
twelve were splenectomized. In Table 3 a summary of all imaging ﬁnd-
ings is provided. Examples of imaging ﬁndings are depicted in Figs. 4
and 5. In ﬁve patients a radiological diagnosis of simple liver cysts was
made. In four patients the distinction between a liver cyst or
gaucheroma could not be made based on the imaging examinations.
All these lesions had a hypodense appearance on non-contrast-
enhanced CT images. Available MRI data showed T1 hypo-intense and
T2 hyperintense signal of the lesions.
In seven cases, the presence of a haemangioma was considered.
These lesions all fulﬁlled the typical imaging characteristics of a
haemangioma on ultrasonography (hyperechoic, hypervascular), ex-
cept for one (no. 11) in which the lesion was described as hypoechoic
and hypervascular. In this case an ultrasound-guided biopsy of the le-
sion was performed, because HCC was suspected. This lesion showed
arterial enhancement after contrast administration on CT. Pathologic
examination proved the lesion to be a gaucheroma.
Focal nodular hyperplasia (FNH)was themain differential diagnosis
based on imaging appearance in three patients. This diagnosis was
conﬁrmed by pathology examination in one (no. 5). All three lesions
showed enhancement on MR imaging after contrast agent administra-
tion, but no clear enhancing central scar was noticed in these cases.
Two US examinations reported hypoechoic lesions and in one case the
lesion was not visible on US.
In two cases, the diagnosis of gaucheromawasmade after excluding
other possible diagnoses. Both patients had multiple lesions in the liver
with a hypodense aspect and both showed calciﬁcations in some of the
lesions. On ultrasound (data available for one gaucheroma case) the le-
sions appeared hyperechoic.
Hepatocellular carcinoma was found and conﬁrmed by pathology
examination in four patients (no. 2, 14, 19, 27). In one patient (no. 27)
the typical HCC characteristics were present on contrast-enhanced CT-
images; multiple strongly enhancing lesions, with wash-out of contrast
in the delayed phases. In cases 14 and 19 themalignant lesions showed
enhancement after contrast agent administration, butwash-outwas not
detected. The focal lesion in case 14 was not clearly visible on ultra-
sound examination. Follow-up MRI showed growth of the lesion,
whichwas an indication for surgery. Case 19 had a focal lesion detected
on US. Further characterization was performed on dynamic scans
and signs of (multifocal) HCC were shown, although wash-out of the
lesions was not present. In the fourth case (no.2) no dynamic examina-
tions were available for review. This lesion was hyperechoic on US
Table 2
Imaging characteristics of splenic lesions found on the different imaging modalities. Abbreviations: NECT: non contrast-enhanced CT. CECT: contrast-enhanced CT. T1 C+: contrast en-
hanced T1 weighted MRI.
Splenic lesions
Imaging characteristics
Patient
number
Solitary/multiple splenic
lesions
CT appearance MRI appearance Ultrasound appearance Differential radiological
diagnosis
1 Multiple NECT: hypodense
CECT: no enhancement
– – Gaucheroma
4 Multiple – T1: mixed hypo-/hyperintense
T1C+: no enhancement
Hyperechoic Gaucheroma
6 Solitary – – Hyperechoic Haemangioma/gaucheroma
7 Multiple NECT: hypodense
CECT: slight enhancement of rim of
the lesion
– Hypoechoic with
hyperechoic rim
Gaucheroma
12 Multiple NECT: hypodense – – Gaucheroma
13 Multiple – T1: mixed hypo-/hyperintense – Gaucheroma
15 Multiple NECT: hypodense with
calciﬁcations
T1: heterogeneous aspect Hypoechoic with
calciﬁcations
Gaucheroma
17 Multiple NECT: hypodense T1: hyperintense Hyperechoic
Hypoechoic with
hyperechoic rim
Gaucheroma/infarction
18 Multiple NECT: hypodense T1: hypointense Hyperechoic
Hypoechoic
Gaucheroma/infarction
20 Multiple NECT: hypodense – Hyperechoic Gaucheroma
22 Multiple – – Hypoechoic with
calciﬁcations
Gaucheroma
25 Multiple NECT: hypodense with
calciﬁcations
T1: hyperintense with
calciﬁcations
– Gaucheroma
28 Multiple NECT: hypodense T1: hyperintense Hypoechoic Gaucheroma
29 Multiple – – Hyperechoic
Isoechoic
Gaucheroma
30 Multiple NECT: hypodense with
calciﬁcations
– Hypoechoic Gaucheroma
31 Multiple NECT: hypodense T2: hyperintense – Gaucheroma
32 Solitary – – Hyperechoic Hemangioma/gaucheroma
33 Multiple NECT: Diffuse hypodense with
calciﬁcations
T1: mixed hypo-/hyperintense – Gaucheroma
34 Multiple NECT: hypodense T1: hyperintense, mixed
hypo-/hyperintense
T2: hypointense
– Gaucheroma
35 Multiple NECT: hypodense
CECT: no enhancement
T1: hypointense
T2: hyperintense
Hyperechoic with
hypoechoic center
Gaucheroma
36 Multiple NECT: hypodense, some with
calciﬁcations
– – Gaucheroma
37 Multiple – T1: hyperintense Hyperechoic Gaucheroma
38 Solitary – T2: hypointense Hyperechoic Gaucheroma
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CT.
4. Discussion
Focal splenic and/or hepatic lesions are a common ﬁnding in GD pa-
tients, detected by various imaging techniques. Reported prevalence
numbers of splenic lesions in GD of different ages range from 18.4% to
33% [14,16–20]. In contrast to these ﬁndings, a study performed in a co-
hort of pediatric GD patients described focal splenic lesions in 4 out of
103 patients (3.9%) on ultrasound examination [21]. This suggests that
with aging, more lesions emerge. The prevalence of focal hepatic lesions
is reported to be lower than that of splenic abnormalities. Neudorfer et
al. found focal lesions in the liver with US examinations in 6.0% of their
population [14]. InMRI studies, prevalence rates of hepatic lesions have
been described and range from 7% [17] to 20% [19]. Our ﬁndings for
splenic lesions are in line with these previous reports. In our adult
cohort, 24% of patients had a focal lesion in the spleen detected on CT,
MRI and/or US. However, the prevalence of focal hepatic lesions of
25% in the Dutch cohort is somewhat higher than reports for
gaucheroma frequencies. An explanation could be the fact that we
reviewed every reported hepatic lesion, not only gaucheroma, resulting
in inclusion of focal liver abnormalities, which are frequently found in
the general population [22,23]. Moreover, as already indicated, ourcohort consists of adult GD patientswith relatively longstanding disease
activity and a substantial percentage of splenectomized patients. In-
deed, when the cohort with lesionswas compared to the groupwithout
lesions, a signiﬁcant difference between disease severity, represented
by a higher percentage of patients with bone complications, higher
baseline chitotriosidase levels and higher baseline SSI-scores was
found. Apparently, these disease severity characteristics weremore im-
portant than age, since there was no signiﬁcant age difference between
the groups. It is well known that advanced liver disease is more com-
mon in patients after splenectomy and with more severe disease
[24,25]. Apparently, these patients are more prone to develop focal le-
sions as well. In line with this, in Israeli patients with milder disease,
focal liver lesions were reported in only 6.0% of the GD population [14].
Because of the retrospective design of this study, the improving im-
aging quality and variety of imaging modalities used over the last
25 years, it was not possible to draw ﬁrm conclusions regarding the evo-
lution of the lesions over time. This is a limitation of the present study.
However, it is fair to say that in general, over a time course of 10 to
20 years, splenic lesionsdonot disappear, despite impressive reductions
in splenic size following treatment with ERT. Neudorfer et al. [14] ob-
served no change in splenic lesions in 43.2% of patients following treat-
ment with ERT when comparing 6 month follow-up US with baseline
ﬁndings. In a pediatric cohort ﬁve patients with hepatic or splenic le-
sions showed no change in appearance or size as effect of ERT during
Table 3
Imaging characteristics of hepatic lesions found on the different imaging modalities. Abbreviations: NECT: non contrast-enhanced CT. CECT: contrast-enhanced CT. T1 C+: contrast en-
hanced T1 weighted MRI.
Hepatic lesions
Imaging characteristics
Patient
number
Solitary/Multiple
hepatic lesions
CT appearance MRI appearance Ultrasound
appearance
Differential radiological/pathological
diagnosis
2 Solitary NECT: hypodense area – Hyperechoic Hepatocellular carcinoma (pathology
examination)
3 Multiple – Calciﬁcations Calciﬁcations Non-speciﬁc ﬁnding, not of clinical
importance
4 Multiple – T1: hypointense Hypoechoic Liver cysts
5 Multiple 1. CECT: arterial
enhancement, sharp
demarquation and
wash-out
2. small cyst
1. T1C+: enhancement in arterial phase, slight
hyperintense signal on diffusion images. Not visible
on T1 and T2, no wash-out.
1. not visible
2. some cysts
1. Focal nodular hyperplasia (pathology
examination)
2. Liver cysts
8 Solitary – T1: small demarquated lesion, cyst – Liver cyst
9 Solitary – T1: hypointense
T2: hyperintense.
T1 C+: sharply demarquated lesion, no contrast
enhancement, slight late enhancement
peripherally
Hyperechoic Haemangioma/gaucheroma
10 Multiple NECT: hypodense T2: Hyperintense Hypoechoic Liver cyst/gaucheroma
11 Solitary CECT: arterial and venous
enhancement of lesion
– Hypoechoic,
hypervascular
Haemangioma/gaucheroma/hepatocellular
carcinoma
Pathology examination: gaucheroma
14 Multiple CECT: arterial
enhancement, central
necrosis
T1: hyperintense
T2: hyperintense
Diffusion: hyperintense
T1 C+: enhancing lesion, no wash-out
Heterogeneous
signal liver
Hepatocellular carcinoma (pathology
examination)
15 Solitary NECT: hypodense lesion
(cyst)
– Hypoechoic Liver cyst
16 Solitary – – Hyperechoic Haemangioma
19 Multiple NECT: hypodense,
calciﬁcations
T1: hyperintense
T2: slightly hyperintense
Diffusion: slightly hyperintense
T1 C+: enhancing lesions, no clear wash-out
Heterogeneous
signal liver,
hypoechoic
lesions
Hepatocellular carcinoma (pathology
examination)
21 Multiple NECT: hypodense,
calciﬁcations
– Calciﬁcations Gaucheroma
22 Solitary – T1: round, sharply demarquated, hyperintense
T1 C+: enhancing lesion
Hypoechoic Focal nodular hyperplasia/gaucheroma
23 Multiple NECT: hypodense T1: hypointense – Gaucheroma/liver cysts
24 Multiple NECT: hypodense – Hyperechoic
nodules;
calciﬁcations
Gaucheroma
26 Solitary – T1: hypointense Hyperechoic,
sharp
demarquation
Haemangioma
27 Multiple NECT: hypodense,
inhomogeneous liver
CECT: strongly enhancing
lesions, wash-out
– Heterogeneous
aspect of liver
Hepatocellular carcinoma (pathology
examination)
28 Multiple NECT: hypodense T1: hypointense Hypoechoic Liver cysts/gaucheroma
29 Solitary – – Hyperechoic Haemangioma
31 Multiple NECT: hypodense T1: hypointense
T2: hyperintense
– Haemangioma/gaucheroma/liver cysts
34 Multiple – T2: hypointense – Liver cysts
35 Solitary – T2: hyperintense. Late enhancement Hyperechoic Haemangioma
38 Multiple – 1. T2: hyperintense T1 C+: contrast enhancement,
no wash-out
2. some hypointense lesions
1. Hypoechoic 1. Focal nodular hyperplasia
2. hemosiderin deposits
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this ﬁnding are the results in pediatric GD patients treated with ERT.
In all patients with splenic abnormalities (21%), the lesions resolved
during follow-up. These changes were detected in a period from
17 months onwards to N4 years [18]. This suggests again a difference
between pediatric and adult patients, pointing towardsmore reversibil-
ity of lesions in a younger population. The presence of splenic lesions in
GD might inﬂuence the response of splenic volume and platelets to
therapy. As is shown by Stein et al. [16], splenic lesions are associated
with a weaker platelet response. Patients with splenic lesions showed
less reduction in splenic size as compared to patients without lesions.The presence of focal splenic lesions is proposed as a determinant of re-
sponse to therapy in GD patients [16].
4.1. Differential diagnosis of splenic lesions
The general differential diagnosis of splenic lesions comprises
inﬂammatory processes, vascular disorders, hematologic disorders, be-
nign neoplasms and malignant neoplasms [26]. Splenic involvement
in lymphoma is the most common splenic malignancy and may be
primary or secondary as commonly occurring in Hodgkin and non-
Hodgkin lymphoma [27–30]. In GD, lymphoma as well as other
Table 4
Imaging criteria used in diagnosing common splenic lesions. Abbreviations: NECT: non contrast-enhanced CT. CECT: contrast-enhanced CT. T1 C+: contrast enhanced T1 weighted MRI.
Splenic lesions
Diagnosis References General characteristics CT appearance MRI appearance US appearance
Hemangioma [26,36] Sharply demarcated lesion
Multiple vascular channels
NECT: hypodense
CECT: enhancement subject to variety; centripetal
enhancement from periphery with persistence on
delayed images/mottled enhancement with areas
remaining hypodense to normal spleen/immediate
homogeneous enhancement
T1: hypo- or isointense
T2: hyperintense
T1 C+: variable enhancement
patterns (as in CECT).
Hypoechoic or
hyperechoic
Splenic cyst [26,36] Well-deﬁned ﬂuid-ﬁlled
space
Usually oval or round
lesion with a thin wall
NECT: isodense to water
CECT: no enhancement
T1: hypointense
T2: hyperintense
T1 C+: no enhancement
Anechoic
Lymphoma [26–30,36] May be primary splenic
lymphoma or secondary.
Multiple lesions or single
lesion
NECT: hypodense, homogeneous
CECT: hypoenhancement of lesion
T1: isointense
T2: hypo- or isointense
T1 C+: hypoenhancement of lesion
Hypoechoic
Gaucheroma [14,17–20,37,38] Clusters of Gaucher cells,
areas of ﬁbrosis, necrosis,
calciﬁcations and iron
deposition.
NECT: isodense, hypodense
CECT: enhancement of lesion with hyperdense rim,
targetlike lesion
T1: hypointense, hyperintense,
isointense, mixed signal intensity
T2: hypointense, hyperintense,
mixed signal intensities. Targetlike
lesions (hypointense center and
hyperintense rim)
T1 C+: peripheral contrast
enhancement or heterogeneous
internal enhancement
Hypoechoic,
hyperechoic or
mixed
echogenicity
Table 5
Imaging criteria used in diagnosing common hepatic lesions. Abbreviations: NECT: non-contrast enhanced CT. CECT: contrast-enhanced CT. T1 C+: contrast enhanced T1 weighted MRI.
Hepatic lesions
Diagnosis References General characteristics CT appearance MRI appearance US appearance
Cavernous
hemangioma
[22,33,39,40] Benign tumor composed of
multiple vascular channels
Sharply demarcated spherical to
ovoid lesion, b10 cm.
Giant hemangioma (N10 cm):
atypical appearance possible,
central ﬁbrous scarring may
prevent complete ﬁll in.
NECT: Same density as blood vessels,
giant hemangiomas may have central
scarring and calciﬁcations.
CECT: Discontinuous peripheral
enhancement, nodular or globular.
Progressive ﬁll-in. Areas of
enhancement same density as the
bloodpool.
T1: iso- or hypointense
to blood
T2: hyperintense
T1 C+: Same
enhancement pattern
as CECT.
Hyperechoic mass with acoustic
enhancement (occasionally iso- or
hypoechoic)
Increased sound transmission
Focal nodular
hyperplasia
[22,33,40] Benign tumor caused by
hyperplastic response to localized
vascular abnormality
Typically in young women
Usually lobulated/well
circumscribed
Central ﬁbrous scar with large
vessels.
NECT: well-deﬁned, hypo- or isodense
to normal liver
CECT: hyperdense in arterial phase
(except central scar), homogeneous
enhancement. In portal and late
phases: isoenhancement. Central scar
hyperdense.
T1: isointense with
hypointense central
scar
T2: isointense or
slightly hyperintense,
hyperintense central
scar (sometimes
hypointense)
T1 C+: Same
enhancement pattern
as CECT.
Non-speciﬁc ill-deﬁned isoechoic
lesion, occasionally hypo- or
hyperechoic.
Central scar may be detected as
hyperechoic. Color Doppler:
spoke-wheel pattern due to central
feeding artery with small vessels
radiating peripherally.
Simple hepatic
cyst
[22,33] Benign, congenital, developmental
lesion derived from biliary
endothelium.
Well-deﬁned ﬂuid-ﬁlled space
Usually oval or round lesion with a
thin wall, often multiple.
NECT: isodense to water (−10 to 10
HU)
CECT: no enhancement
T1: hypointense
T2: hyperintense
T1 C+: no
enhancement
Anechoic
Hepatocellular
carcinoma
[41,42] Characteristic features:
hypervascular lesion, mosaic
pattern, presence of a tumoral
capsule, early arterial
enhancement and fast wash-out
NECT: isodense/hypodense ± necrosis,
fat, calciﬁcation.
CECT: heterogeneous diffuse
enhancement in arterial phase,
wash-out on delayed images
T1: hypointense, but
may also appear iso- or
hyperintense
T2: generally
hyperintense.
Regenerative nodules
are hypointense
T1 C+: heterogeneous
enhancement in
arterial phase,
wash-out on delayed
images
Mixed echogenicity. Peripheral halo,
mosaic pattern and lateral shadowing.
Color Doppler: hypervascularity and
tumor shunting.
Gaucheroma [19,21,43–45] Clusters of Gaucher cells, areas of
ﬁbrosis, necrosis and iron
deposition.
NECT: no information available
CECT: hyperdense, enhancing lesions
T1: hypointense
T2: hyperintense,
isointense
Hyperechoic
Hypoechoic
Targetlike lesions
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Fig. 6. Proposol for follow-up algorithm for focal hepatic lesions in GD patients. *Imaging criteria are described in Table 5. In case of an uncertain diagnosis, the ‘no’-pathway is followed.
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general population [4,5,31,32]. Thus, it would be helpful to characterize
gaucheroma based upon imaging features. The various studies describ-
ing imaging features of splenic lesions are summarized in Table 4.
As shown, imaging characteristics of focal lesions in GD patients are
variable. This is probably explained by differences in composition
of each lesion, depending on the amount of ﬁbrosis, necrosis,
dilated sinusoids and Gaucher macrophages in the lesion. As a
result, differentiating between a focal splenic Gaucheroma and a
splenic lymphoma solely based on imaging characteristics is not
possible. The most important factor is growth of the lesion over time
in case of malignancy. Presence of laboratory abnormalities
including an M-protein or systemic symptoms such as weight loss,
malaise and fever may also be signs of a malignant etiology of the
lesion. No malignant lesions of the spleen have been diagnosed in our
cohort.
4.2. Differential diagnosis of hepatic lesions and hepatocellular carcinoma
In 24% of the current population lesions were reported in the liver,
including gaucheroma and other abnormalities [22,33]. A summary of
imaging characteristics is given in Table 5. As for splenic lesions,
gaucheroma of the liver possess variable imaging characteristics and it
is therefore difﬁcult to distinguish a gaucheroma from another lesion.
Since it is shown that GD patients have a higher risk of developing
HCC [34,35], which were found in four patients in our cohort, it is im-
portant to emphasize the imaging characteristics of these lesions. Un-
fortunately, as described in the results, not all four HCC cases in GD
patients in our cohort did present with typical HCC imaging features,
on dynamic CT/MRI examination, which consist of heterogeneous dif-
fuse enhancement in arterial phase and wash-out of contrast agent on
delayed images. This indicates the need for watchful surveillance of
focal hepatic lesions, especially in patients who underwent previous
splenectomy.
4.3. Follow-up recommendations
In summary, focal lesions in liver or spleen are common in GD1
patients and are not always of benign etiology. In case of focal splenic le-
sionswith no apparent clinical signs or symptoms of a possible lympho-
ma, a gaucheroma is the most likely diagnosis and routine follow-up isnot necessary. Since an isolated splenic lymphoma can be relatively
symptom-free, follow-up imaging to detect growth within 6 months
could be considered. Needless to say, every indication of growth or
resistance to treatment should prompt the clinician to reevaluate the le-
sions. In Fig. 6 a proposal of a follow-up algorithm in case of focal liver
lesions is provided. Since splenectomized patients are considered to
have a higher risk in developing HCC, screening is recommended in ac-
cordance with the current guidelines for high risk populations [46].
In case of a lesion N1 cm, further work-up comprising dynamic con-
trast-enhanced CT- or MRI-scanning is performed. When results of one
dynamic contrast-enhanced study are inconclusive, performing a sec-
ond dynamic contrast-enhanced study should be considered. Lesions
that remain indeterminate despite proper imaging work-up require
percutaneous imaging-guided biopsy.
In small nodules (b1 cm) one might opt for close imaging surveil-
lance to detect growth. Patients with an intact spleen do not carry the
higher HCC-risk.When US characteristics show typical signs of a benign
lesion (i.e. anechoic well-deﬁned lesion is a liver cyst) in a GD patient
with an intact spleen, follow-up is not necessary. In case of an atypical
appearance of the lesion, it is recommended to monitor the lesion fre-
quently, i.e. half-yearly, to detect growth or change in appearance. A
much-used practical approach in our center is to discharge patients
from follow-up after 2 years of biannual US surveillance without any
signs of growth or change of the lesion. In case of any possible sign of
malignancy, such as growth of the lesion or the appearance of clinical
signs or symptoms (i.e. weight loss, increasing α-fetoprotein levels),
we strongly recommend a contrast-enhanced examination to charac-
terize the lesion. Biopsy of a lesion should be considered when results
are inconclusive.5. Conclusion
We conclude that splenic and hepatic lesions are common in GD and
are more frequent in patients with more severe disease. A gaucheroma
is mainly a diagnosis of exclusion, especially in the liver. In our GD1 co-
hort, followed for several years, splenic lesions were always benign,
with gaucheroma being the most likely diagnosis. Lesions in the liver
are also gaucheroma, but other lesions occur as well. The variety of im-
aging characteristics of gaucheroma mandates a rigorous follow-up. A
proposal for follow-up of focal hepatic lesions in GD patients is
57M. Regenboog et al. / Blood Cells, Molecules and Diseases 60 (2016) 49–57provided,based upon imaging characteristics and growth of the lesion,
which aims to detect a malignancy at an early stage.
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